Blood coagulation

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 17, Issue 3, 2003, Pages 369-383

  Norris, Lucy A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Coagulation; Fibrin; Thrombin; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRIN; FIBRINOGEN; PLASMIN; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; SERINE PROTEINASE; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLOOD CLOTTING; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FIBRIN CLOT; FIBRIN DEPOSITION; FIBRIN FORMATION; FIBRINOLYSIS; GENETIC PARAMETERS; HEMOSTASIS; HUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

EID: 0038043139     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(03)00014-2     Document Type: Review

References (82)

1. Lammele B, Wuihlemin WA, Huber I et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency: A study on 74 subjects from 14 Swiss families. Thrombosis and Haemostasis 1991; 65: 117-121.
2. Bugge TH, Xiau Q, Kombrinck KW et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell associated initiator of blood coagulation. Proceedings of the National Academy of Sciences of the USA 93: 6258-6263.
3. Camerer E, Kolsto AB & Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thrombosis Research 1996; 81: 1-41.
4. Morrisey JH. Tissue factor: An enzyme cofactor and a true receptor. Thrombosis and Haemostasis 2001; 86: 66-74.
5. Heinrich J, Balleisen L, Schulte H et al. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arteriosclerosis and Thrombosis 1994; 14: 54-59.
6. Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart study. Lancet 1986; ii: 533-537.
7. Morrisey JH. Plasma factor VIIa: Measurement and clinical significance. Haemostasis 1996; 26: 66-71.
8. Cooper DN, Millar DS, Wacey A et al. Inherited factor VII deficiency: Molecular genetics and pathophysiology. Thrombosis and Haemostasis 1997; 78: 151-160.
9. Iacoviello L, Di Castelnuovo A, De Kniff P et al. Polymorphisms of the factor VII gene and the risk of myocardial infarction. New England Journal of Medicine 1998; 338: 79-85.
10. Corral J, Gonzalez-Conejero R, Lozano ML et al. Genetic polymorphisms of factor VII are not associated with arterial thrombosis. Blood Coagulation and Fibrinolysis 1998; 9: 267-272.
11. Colman RW, Clowes AW, George JN et al. Overview of haemostasis. In Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN et al (eds) Haemostasis and Thrombosis, Basic Principles and Clinical Practice, 4th edn, pp 3-16, New York: Lippincott/Williams & Wilkins, 2001.
12. Scott CF, Silver LD, Purdon AD et al. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. Journal of Biological Chemistry 1985; 260: 10 856-10 863.
13. Asakai R, Chung DW, Davie EW & Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. New England Journal of Medicine 1991; 325: 153-158.
14. Gailani J & Broze Jr GR. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912.
15. Meijers JCM, Tekelenburg WLH, Bouma BN et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. New England Journal of Medicine 2000; 342: 696-701.
16. Colman RW. Biologic activities of the contact factors in vivo: Potentiation of hypotension, inflammation and fibrinolysis and inhibition of cell adhesion, angiogenesis, and thrombosis. Thrombosis and Haemostasis 1999; 82: 1568-1577.
17. Neisheim M, Pittman DD, Giles AR et al. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin activated platelets. Journal of Biological Chemistry 1991; 266: 17 815-17 820.
18. Hamer RJ, Koedam JA, Beeser-Visser NH et al. The effect of thrombin on the complex between factor VIII and von Willebrand factor. European Journal of Biochemistry 1987; 167: 253-259.
19. Kane WH. Factor V. In Colman RW et al (eds) Haemostasis and Thrombosis, Basic Principles and Clinical Practice, 4th edn, pp 157-169, New York: Lippincott/Williams and Wilkins, 2001.
20. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
21. Neisheim ME, Taswell JB & Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. Journal of Biological Chemistry 1979; 254: 10 952-10 962.
22. Doyle MF & Haley PE. Meizothrombin: Active intermediate formed during prothrombinase-catalysed activation of prothrombin. Methods in Enzymology 1993; 222: 299.
23. Bauer KA. Activation markers of coagulation. Baillière's Clinical Haematology 1999; 12: 387-406.
24. Poort SR, Rosendaal FR, Reitsma PH & Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis. Blood 1996; 388: 3698-3703.
25. Brummel KE, Paradis SG, Butenas S & Mann KG. Thrombin functions during tissue factor induced blood coagulation. Blood 2002; 100: 148-152.
26. Tulinsky A. Molecular interactions of thrombin. Seminars in Thrombosis and Haemostasis 1996; 22: 117-124.
27. Weisel J. Fibrin assembly. Lateral aggregation and the role of two pairs of fibrinopeptides. Journal of Biophysics 1986; 50: 1079.
28. Clark RAF. Wound repair. In Clark RAF (ed.) The Molecular and Cellular Biology of Wound Repair, p 617, New York: Plenum Press 1996.
29. Wojtukiewicz MA, Sierko E, Klement P & Rak J. The haemostatic system and angiogenesis in malignancy. Neoplasia 2001; 3: 371-384.
30. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagulation and Fibrinolysis 1995; 6(supplement): S7-S13.
31. Hamik A, Setiadi H, Bu GJ et al. Down regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and low density lipoprotein receptor-related protein. Journal of Biological Chemistry 1999; 74: 4962-4969.
32. Fuchs H, Shiffman M & Pizzo S. In vivo catabolism of alpha 1-proteinase inhibitor-trypsin, antithrombin-thrombin and alpha2macroglobulin-methylamine. Biochimica et Biophysica Acta 1982; 716: 151-157.
33. Lopez Y, Paloma MJ, Rifon J et al. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thrombosis Research 1999; 93: 71-78.
34. Kauffman R, Veltkamp J, Van Tilburg N & Van Es L. Acquired antithrombin III deficiency and thrombosis in the nephritic syndrome. American Journal of Medicine 1978; 65: 617-613.
35. Francis C, Pellegrini V, Harris C et al. Prophylaxis of venous thrombosis following total hip and total knee replacement using antithrombin III and heparin. Seminars in Hematology 1991; 28: 39-45.
36. Harper P, Luddington R, Daly M et al. The incidence of dysfunctional antithrombin variants: Four cases in 210 patients with thromboembolic disease. British Journal of Haematology 1991; 77: 360-364.
37. Kisiel W. Human plasma protein C: Isolation, characterisation and mechanisms of activation by α-thrombin. Journal of Clinical Investigation 1979; 64: 761-769.
38. Esmon CT. The endothelial cell protein C receptor. Thrombosis and Haemostasis 2000; 83: 639-643.
39. Wu KK & Matijevic-Aleksic N. Thrombomodulin: A linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Annals of Medicine 2000; 32(supplement): 73-77.
40. Ye J, Esmon NL, Esmon CT & Johnson AE. The active site of thrombin is altered upon binding to thrombomodulin: Two distinct structural changes are detected by fluorescence but only one correlates with protein C activation. Journal of Biological Chemistry 1991; 266: 23 016-23 021.
41. Liaw PCY, Neuenschwander PF, Smirnov MD & Esmon CT. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. Journal of Biological Chemistry 2000; 275: 5447-5452.
42. Walker FJ. Regulation of activated protein C by a new protein: A role for bovine protein X. Journal of Biological Chemistry 1980; 255: 5521-5524.
43. Walker FJ & Fay PJ. Regulation of blood coagulation by protein C system. FASEB Journal 1992; 6: 2561-2567.
44. Vehar GA & Davie EW. Preparation and properties of bovine factor VIII. Biochemistry 1980; 19: 401-410.
45. Walker FJ, Sexton PW & Esmon CT. Inhibition of blood coagulation by activated protein C through selective inactivation of activated factor V. Biochimica et Biophysica Acta 1979; 571: 333-342.
46. Amano K, Michnick DA, Moussalli M & Kaufman RJ. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C(APC)-mediated inactivation: Implications for the APC resistance test. Thrombosis and Haemostasis 1998; 79: 557-563.
47. R506Q by activated protein C. Journal of Biological Chemistry 1995; 270: 21158-21166.
48. Dahlbäck B. Resistance to activated protein C as a risk factor for thrombosis: Molecular mechanisms, laboratory investigation, and clinical management. Seminars in Haematology 1997; 34: 217-234.
49. Zivelin A, Griffin JH, Xu X et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402.
50. Reitsma PH, Bernardi F, Doig RG et al. Protein C deficiency: A database of mutations, 1995 update. On behalf of the subcommittee on plasma coagulation inhibitors of the scientific and standardisation committee of the ISTH. Thrombosis and Haemostasis 1995; 73: 876-889.
51. Sehigsohn U, Berger A, Abend M et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. New England Journal of Medicine 1984; 310: 559-562.
52. Middlethorp S, Buller HR, Prins MH & Hirsh J. Approach to the thrombophilic patient. In Colman RW, et al (eds) Haemostasis and Thrombosis, Basic Principles and Clinical Practice, 4th edn, pp 1085-1100, New York: Lippincott/Williams & Wilkins, 2001.
53. Dälhlback B & Stenflo J. High molecular weight complex in human plasma between Vitamin K-dependent protein S and complement component C4b-binding protein. Proceedings of the National Academy of Sciences of the USA 1981; 78: 2512-2516.
54. Comp PC. Laboratory evaluation of protein S status. Seminars in Thrombosis and Haemostasis 1990; 16: 177-181.
55. Simmonds RE, Zoller B, Ireland H et al. Genetic and phenotypic analysis of a large (122 member), protein S deficient kindred provides an explanation for the familial coexistence of type I and type III plasma phenotypes. Blood 1997; 89: 4364-4370.
56. Biguzzi E, Merati G, Liaw PC et al. A 23bp insertion in the endothelial protein C receptor (EPCR) gene in patients with myocardial infarction and deep vein thrombosis. Thrombosis and Haemostasis 2001; 86: 945-948.
57. Pixley RA, Schapira M & Colman RW. The regulation of human factor XIIa by plasma proteinase inhibitors. Journal of Biological Chemistry 1985; 260: 1723-1729.
58. Scott CF, Schapira M, James HL et al. Inactivation of XIa by plasma protease inhibitors: Predominant role of α-I-protease inhibitor and protective effect of high molecular weight kininogen. Journal of Clinical Investigation 1982; 69: 844-852.
59. James K. Alpha2-macroglobulin and its possible importance in the immune system. Trends in Biochemical Science 1980; 5: 43.
60. Donaldson VH & Evans RR. Biochemical abnormality in hereditary angioneurotic edema. American Journal Medicine 1963; 35: 37.
61. Castellino FJ. Biochemistry of human plasminogen. Seminars in Thrombosis and Haemostasis 1984; 10: 18-23.
62. Robbins KC, Summaria L, Hseih B & Shah R. The peptide chains of human plasmin: Mechanism of activation of human plasminogen to plasmin. Journal of Biological Chemistry 1967; 242: 2333.
63. Mandle RJ Jr & Kaplan AP. Hageman factor dependent fibrinolysis. Generation of fibrinolytic activity by the interaction of human factor XI and plasminogen. Blood 1979; 54: 850.
64. Colman RW. Activation of plasminogen or plasma kallikrein. Biochemical and Biophysical Research Communications 1979; 351: 273.
65. Colman RW, Bugdascorian A, Talamo RC et al. Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikerin associated with abnormalities of the Hageman factor dependent pathways. Journal of Clinical Investigation 1975; 56: 1650.
66. Saito H, Ratnoff O, Waldmann A & Abraham JP. Fitzgerald trait: Deficiency of a hitherto unrecognised agent Fitzgerald factor, participating in surface mediated reactions of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability (PF/dil). Journal of Clinical Investigation 1975; 55: 1082.
67. Camiolo SM, Thorsen S & Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proceedings of the Society of Experimental Biology and Medicine 1971: 138: 277-280.
68. Kaplan KL, Mather T, DeMarco L & Solomon S. Effect of fibrin on endothelial cell production of prostacyclin and tissue plasminogen activator. Arteriosclerosis 1989; 9: 43.
69. Levin EG, Marzec U, Anderson J & Harker LA. Thrombin stimulates tissue plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells. Journal of Clinical Investigation 1984; 74: 1988.
70. Amery A, Vermylen J, Maes H & Verstraete M. Enhancing the fibrinolytic activity of human blood by occlusion of blood vessels. Thrombosis Diathesis Haemorrhagica 1962; 7: 70.
71. Stahl A & Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Research 1994; 54: 3066-3071.
72. Dano K, Andreason PA, Grondahl-Hansen J et al. Plasminogen activators, tissue degradation and cancer. Advances in Cancer Research 1985; 44: 139-266.
73. Wiman B & Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. European Journal of Biochemistry 1978; 84: 573.
74. 2antiplasmin-plasmin complex determination in human plasma. Fibrinolysis 1992; 6(supplement 3): 94-96.
75. Aoki N & Harpel PC. Inhibitors of the fibrinolytic enzyme system. Seminars in Thrombosis and Haemostasis 1984; 10: 24.
76. Chandler WL, Trimble SL, Loo SC et al. Effect of PAI-I levels on the molar concentrations of active tissue plasminogen activator (tPA) and t-PA/PAI-I complex in plasma. Blood 1990; 76; 930-937.
77. Delehrter TD & Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. Journal of Clinical Investigation 1986; 77: 165.
78. Emeis JJ & Kooistra T. Interleukin-I and lipopolysacharide induce an inhibitor of tissue type plasminogen activator in vivo and in cultured endothelial cells. Journal of Experimental Medicine 1986; 163: 1260.
79. Kruithof EK, Baker MS & Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor 2. Blood 1985; 86: 4007-4024.
80. Bajzar L, Morzer J & Nesheim M. Purification and characterisation of TAFI, thrombin activatable fibrinolysis inhibitor. Journal of Biological Chemistry 1995; 270: 14477.
81. Wang P, Boffa MB, Bajzar L et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin activatable fibrinolysis inhibitor. Journal of Biological Chemistry 1998; 273: 27176.
82. Bajzar L, Nesheim ME & Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093.